相关实验视频
Updated: Sep 13, 2025

11:12
Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation
Published on: July 16, 2014
22.6K
帕金森病患者使用抗帕金森药物的条件疼痛调节的变化
Eiichirou Urasaki1, Yasushi Miyagi1, Junji Kishimoto2
1Department of Neurosurgery, Fukuoka Mirai Hospital, Medical Co. LTA (Living Together Association), Fukuoka, Japan.
eNeurologicalSci
|July 29, 2025
概括
帕金森病患者在服用抗帕金森病 (PD) 药物时经历了改善的疼痛调节. 这项研究发现,药物增强了"疼痛抑制疼痛"的能力,通过皮肤静止期 (CSP) 和数值评分表 (NRS) 来衡量.
科学领域:
- 神经科学是一个神经科学.
- 疼痛研究 疼痛研究
- 药理学 药理学是指药理学的学科.
背景情况:
- 帕金森病 (PD) 经常与疼痛有关,可能是由于多巴胺缺乏降低疼痛值.
- 抗PD药物的对内源性疼痛抑制系统,特别是条件性疼痛调制 (CPM) 的影响仍未得到充分研究.
研究的目的:
- 为了评估帕金森病患者的条件疼痛调制 (CPM),使用皮肤静止期 (CSP) 和数值评分尺度 (NRS).
- 为了确定抗帕金森病 (PD) 药物对CPM的影响.
主要方法:
- 在40名PD患者中记录的CSP在药物和药物停止条件下.
- 评估了CSP和NRS的变化,使用电测试刺激和冷压作为条件刺激.
- 在冷压过程中解释了缩短的CSP持续时间或减少的CSP得分作为客观的CPM反应.
主要成果:
- 在冷压过程中CSP持续时间的缩短在药物启动条件下明显大于药物关闭条件.
- 在CSP持续时间的变化与NRS疼痛得分的变化有显著的相关性.
- 有条件的冷压疼痛在药物状态下显著降低了CSP得分.
结论:
- 冷压期间CSP的动态变化表明,抗PD药物可能会增强帕金森病患者的CPM能力.
- 研究结果表明,PD药物可以缓解疼痛症状的潜在机制.
相关概念视频
Parkinson's Disease: Treatment
381
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
381
Parkinson's Disease: Overview
710
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
710
Analgesia and Pain Management
803
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
803
Neural Regulation
40.1K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
40.1K
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
446
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
446

